On May 27, 2025, BioLineRx Ltd. reported its unaudited financial results for the first quarter ended March 31, 2025. The company posted a net income of $5.127 million for the quarter, a significant improvement compared to a net loss of $(0.696) million in Q1 2024.
Total revenues for Q1 2025 were $0.255 million, primarily from royalties, reflecting the transition to a royalty-based revenue model following the out-licensing of APHEXDA. This contrasts with $6.855 million in Q1 2024, which included direct product sales.
The company's operating expenses saw substantial reductions, with sales and marketing expenses dropping to zero from $6.342 million in Q1 2024 due to the cessation of U.S. commercial operations. Research and development expenses also decreased to $1.623 million. BioLineRx ended the quarter with $9.036 million in cash and equivalents and continues to evaluate new assets for in-licensing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.